Wiener Lung Krebsmittel Is Supposed to "Help Many People"

stol.it

Factuality

Ownership

Its starting point was the innovation in the Vienna laboratories of Boehringer Ingelheim: around 12,000 compounds were investigated for possible efficacy against the type of lung cancer, which affects relatively many non-smokers, the then head of global Boehringer cancer research and now "Senior Executive Scientist", Norbert Kraut, in conversation with the APA. In the end, Zangertinib was found, which now operates under the brand name Hernexeos.…

Salzburger Nachrichten

Factuality

Ownership

Every year, around 40,000 people worldwide receive the diagnosis of "non-small cell lung cancer" (NSCLC) including a particular genetic characteristic called HER2 mutation. From 2017, Viennese cancer researchers have targeted the search for a small molecule that can render such cancer cells harmless. They found it and recently received – surprisingly fast – drug approvals in the USA, China and Japan. Europe should follow in about two years.